Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome (PPB)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Children's Research Institute
Sponsor:
Information provided by (Responsible Party):
D. Ashley Hill, M.D., Children's Research Institute
ClinicalTrials.gov Identifier:
NCT00565903
First received: November 29, 2007
Last updated: July 28, 2016
Last verified: July 2016
  Purpose
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined. We are working to identify the genetic factors which may contribute to the development of this rare tumor.

Condition
Pleuropulmonary Blastoma
Cystic Nephroma
Sertoli-Leydig Cell Tumor of Ovary
Medulloepithelioma
Embryonal Rhabdomyosarcoma of Cervix
Goiter
Sarcoma
Pineoblastoma
Pituitary Tumors
Wilms Tumor

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome

Resource links provided by NLM:


Further study details as provided by Children's Research Institute:

Primary Outcome Measures:
  • Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome. [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
We are collecting blood samples or saliva samples. When available, we also collect tumor samples from prior surgical procedures.

Estimated Enrollment: 2000
Study Start Date: March 2005
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Detailed Description:
Studies of inherited cancer syndromes have provided unique opportunities to uncover and explain important cellular pathways with broad relevance to both sporadic cancers and human development. This proposal studies the cancer predisposition syndrome originally described as a familial form of pleuropulmonary blastoma (PPB). PPB is a rare, aggressive lung cancer that affects young children. Children with PPB and/or their family members are at increased risk for a number of rare conditions, including Wilms tumor, rhabdomyosarcoma, brain tumors, ovarian tumors and nodular hyperplasia of the thyroid gland. In 2009, we mapped a PPB locus and identified germline, loss of function mutations in one copy of DICER1 as the genetic basis of this syndrome. DICER1 encodes a protein that performs the final critical step in maturation of microRNAs (miRNAs). miRNAs are an important form of gene regulation. The syndrome's varied nature is likely attributable to the various roles of miRNAs during different developmental and/or functional circumstances. This study focuses on defining the full phenotype of this cancer predisposition syndrome including penetrance, expressivity in children and adults, pathologic classification of disease and spectrum of predisposing DICER1 mutations. Improved understanding of the clinical and genetic features of this cancer predisposition syndrome is essential to facilitate early diagnosis when the diseases are most curable, and to create genetic counseling and educational materials to guide medical care.
  Eligibility

Ages Eligible for Study:   up to 95 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Families who have a child or adult with pleuropulmonary blastoma or cystic nephroma are invited to participate.
Criteria

Inclusion Criteria:

  • Child or adult diagnosed with pleuropulmonary blastoma, cystic nephroma, embryonal rhabdomyosarcoma of uterine cervix, ovarian Sertoli-Leydig tumor or gynandroblastoma, pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma, medulloepithelioma, Wilms tumor, germline or mosaic DICER1 mutation

Exclusion Criteria:

  • child or adult who does not fit inclusion criteria as listed above
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00565903

Contacts
Contact: Dana Ashley Hill, M.D. 202-476-2051 dashleyhill@gmail.com
Contact: Amanda Field 202-476-2051 afield@childrensnational.org

Locations
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: D Ashley Hill, MD    202-476-2051    dashill@childrensnational.org   
Contact: Mandy Field, BA, MPH    202-476-2051    afield@childrensnational.org   
Principal Investigator: Ashley Hill, MD         
Sponsors and Collaborators
D. Ashley Hill, M.D.
Investigators
Study Chair: D. Ashley Hill, MD Children's Research Institute
Study Director: Yoav Messinger, MD Children's Hospital and Clinics of Minnesota
  More Information

Additional Information:
Responsible Party: D. Ashley Hill, M.D., MD, Division Chief Pathology, Children's Research Institute
ClinicalTrials.gov Identifier: NCT00565903     History of Changes
Other Study ID Numbers: 05-0192 / 201012830 
Study First Received: November 29, 2007
Last Updated: July 28, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Sequence data deposited in ClinVar upon publication. Publication of all final results in NIHMS

Keywords provided by Children's Research Institute:
pleuropulmonary blastoma
PPB
cystic nephroma
DICER1
miRNA

Additional relevant MeSH terms:
Rhabdomyosarcoma
Wilms Tumor
Pituitary Neoplasms
Pinealoma
Sertoli-Leydig Cell Tumor
Leydig Cell Tumor
Ovarian Neoplasms
Rhabdomyosarcoma, Embryonal
Neuroectodermal Tumors, Primitive
Pulmonary Blastoma
Myosarcoma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma
Neoplasms, Complex and Mixed
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplastic Syndromes, Hereditary
Kidney Diseases
Urologic Diseases
Genetic Diseases, Inborn
Endocrine Gland Neoplasms
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms

ClinicalTrials.gov processed this record on December 06, 2016